Investor Information – Abzena

Edison Feed

Share Price

Downloads

Abzena Annual Report 2016

The Company's Annual Report for the year ended 31 March 2016 was released on 15 June 2016

Business Model – Revenue Generating

Abzena is a revenue generating life sciences group with its headquarters in the UK and two sites in the US. The Group offers a range of complementary services and technologies for the selection, development and manufacture of biopharmaceuticals. These provide two sources of income for the Group:

  • Fee for service income from fixed price and full time equivalent based contracts
  • Technology licence revenues from the development and commercialisation of Abzena inside products – products whose properties have been enhanced with the Group’s proprietary technologies

Read more on Abzena inside

Trading and business update

Antibody manufacturing development agreement signed with UCL

Abzena Signs New ThioBridge License Agreement

Interested in our services? Get In Touch